Adobe
Assistant Vice President Financial Services and Insurance
Adobe
Financial Services Industry - Banking Lead
Neo Group Nov 1, 2014 - Apr 2017
Senior Vice President and Partner
Eduventures Jan 2013 - Oct 2014
Managing Vice President Sales and Business Development
Masergy 2014 - 2014
Sales Consultant
Education:
Arizona State University 1989 - 1992
Bachelors, Pre Law, Political Science, Communications
Northeastern University 1988 - 1989
Skills:
Competitive Analysis Business Development Strategy Customer Insight Management Analytics Saas Lead Generation Segmentation Leadership Crm Strategic Partnerships Sales Process Sales Management Marketing Vertical Marketing Sales Operations Marketing Strategy B2B Fmcg Digital Strategy Sales and Marketing Leadership Online Marketing Web Analytics Direct Marketing
Todd R. Golub - Newton MA, US Phillip G. Febbo - Jamaica Plain MA, US Kenneth N. Ross - Boston MA, US William R. Sellers - Chestnut Hill MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q001/68 G01N033/53
US Classification:
435 6, 435 71
Abstract:
Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
Daphne Winifred Bell - Arlington MA, US Daniel A. Haber - Chestnut Hill MA, US Pasi Antero Janne - Newton MA, US Bruce E. Johnson - Brookline MA, US Thomas J. Lynch - Newton MA, US Matthew Meyerson - Concord MA, US Juan Guillermo Paez - Boston MA, US William R. Sellers - Chestnut Hill MA, US Jeffrey E. Settleman - Newton MA, US Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6, 424 91, 435 912
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Prostate Cancer Diagnosis And Outcome Prediction By Expression Analysis
Todd R. Golub - Newton MA, US Phillip G. Febbo - Jamaica Plain MA, US Kenneth N. Ross - Boston MA, US William R. Sellers - Chestnut Hill MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
Daphne Winifred Bell - Arlington MA, US Daniel A. Haber - Chestnut Hill MA, US Pasi Antero Janne - Newton MA, US Bruce E. Johnston - Brookline MA, US Thomas J. Lynch - Newton MA, US Matthew Meyerson - Concord MA, US Juan Guillermo Paez - Boston MA, US William R. Sellers - Chestnut Hill MA, US Jeffrey E. Settleman - Newton MA, US Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Mark A. Rubin - Cambridge MA, US Francesca Demichelis - Cambridge MA, US Levi A. Garraway - Newton MA, US William R. Sellers - Brookline MA, US
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
Daphne Winifred Bell - Arlington MA, US Daniel A. Haber - Chestnut Hill MA, US Pasi Antero Janne - Newton MA, US Bruce E. Johnston - Brookline MA, US Thomas J. Lynch - Newton MA, US Matthew Meyerson - Concord MA, US Juan Guillermo Paez - Boston MA, US William R. Sellers - Chestnut Hill MA, US Jeffrey E. Settleman - Newton MA, US Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
Daphne Winifred Bell - Arlington MA, US Daniel A. Haber - Chestnut Hill MA, US Pasi Antero Janne - Newton MA, US Bruce E. Johnston - Brookline MA, US Thomas J. Lynch - Newton MA, US Matthew Meyerson - Concord MA, US Juan Guillermo Paez - Boston MA, US William R. Sellers - Chestnut Hill MA, US Jeffrey E. Settleman - Newton MA, US Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA Dana Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 61
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Prostate Cancer Diagnosis And Outcome Prediction By Expression Analysis
Todd Golub - Newton MA, US Phillip Febbo - Jamaica Plain MA, US Kenneth Ross - Boston MA, US William Sellers - Chestnut Hill MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
Name / Title
Company / Classification
Phones & Addresses
William W. Sellers Family And General Dentistry
Lisa Vouras DMD Dentists' Office · Dentists
85 Woburn St, Reading, MA 01867 781 944-4940
William V. Sellers
EMERALD HILLS PASTURE, LTD
William Raj Sellers
William Sellers MD Internist
250 Massachusetts Ave, Cambridge, MA 02139 617 871-3938
William C Sellers
SPRINGHILL GROUP LTD
William V Sellers
BLUE GILL RENTALS, LTD
William G. Sellers
A. KNIGHT HAWK SECURITY LC
William L. Sellers President
LEADING EDGE VENTURES, INC
225 Tpke St, Canton, MA 02021 19 Cardinal St, Winchester, MA
William L. Sellers President
LEADING EDGE WORLD TRADE SINGAPORE, INC
35 Highland Cir, Needham, MA 02194 19 Cardinal St, Winchester, MA
250 Massachusetts Ave, Cambridge, MA 02139 617 871-3938 (Phone)
Certifications:
Internal Medicine, 1989 Medical Oncology, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School University of Massachusetts / Worcester Campus Graduated: 1986 Medical School University Of California-San Francisco Graduated: 1986 Medical School Dana Farber Canc Inst-Harva Graduated: 1986
Dr. William W Sellers, Reading MA - DMD (Doctor of Dental Medicine)
Mr. Sellers works in Winston-Salem, NC and specializes in Pediatrics. Mr. Sellers is affiliated with Novant Health Forsyth Medical Center and Wake Forest Baptist Medical Center.
We present a new approach that combines two separate biomechanical techniques to demonstrate that true running gaits would probably lead to unacceptably high skeletal loads in T-Rex, study leader William Sellers said.
Date: Jul 18, 2017
Category: Science
Source: Google
Novartis looking to prime the immune system to battle cancer
The company is already a leader in targeted therapies, drugs that attack specific tumors based on their genetic mutations, an effort led by Dr. William Sellers, the Cambridge-based global head of oncology research. Now, with the addition of Dranoff, who will work closely with Sellers, Novartis plans
This is a huge help for any sort of reconstruction, lead author William Sellers told Discovery News. We now have a number that suggests how much flesh to add to the bones and that should help people produce animals that are the right balance of too fat or too thin.
Date: Jun 06, 2012
Source: Google
Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue ...
on how new or existing cancer drugs might best be used in patients. "Without access to a systematically collected set of molecular data, researchers can't match experiments from cell lines with patient tumors when new medicines become available," said William Sellers, Global Head of Oncology, NIBR.